Menu

Sign in

Sign in

Contact us

Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future

Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future

Another embarrassing and costly blunder has befallen Celgene.

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorization in Europe for the Treatment of X–Linked Hypophosphatemia in Children

TOKYO and LONDON and NOVATO, Calif.

First medicine to treat neonatal diabetes

First medicine to treat neonatal diabetes

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for ...

ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial

ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial

WESTMINSTER, Colo.

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

Geneva, Switzerland and Boston, MA - 26 February, 2018 - ObsEva SA (NASDAQ.

Watch out for this antibiotic if you have heart disease, FDA says

Watch out for this antibiotic if you have heart disease, FDA says

People with heart disease need to be careful about using the common antibiotic clarithromycin, the Food and Drug Administration said Thursday.

Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide

Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide

Bagsværd, Denmark, 22 February 2018 - Novo Nordisk today announced the headline results from PIONEER 1, the first phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes.

Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1

Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1

Merck & Co buys Australian I-O firm Viralytics for $394 million

Merck & Co buys Australian I-O firm Viralytics for $394 million

Merck & Co (NYSE.

Aspirin just as good as rivaroxaban for preventing clots after hip, knee surgery

Aspirin just as good as rivaroxaban for preventing clots after hip, knee surgery

he expensive anti-clotting drug Xarelto (rivaroxaban) is no better than common aspirin when it comes to preventing painful and, potentially, deadly clots in people who have just had total hip ...

Anti-bacterial kitchen sprays and wipes are a waste of money, claims TV doctor as experiment reveals poisonous bugs return within an hour

Anti-bacterial kitchen sprays and wipes are a waste of money, claims TV doctor as experiment reveals poisonous bugs return within an hour

Anti-bacterial kitchen sprays and wipes may be a waste of money, according to TV doctor Michael Mosley.

Gout drug could help treat heart failure

Gout drug could help treat heart failure

Drug repurposing is one of the fastest and most effective routes to new medical treatments.

57 58 59 606162 63 64 65

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote